BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...social media campaign by patients advocating for access to the therapy. Positive Phase I data for Ilya’s...
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

...contrast, she expects Ilya’s product will need to be applied about once every three days. Ilya...
...turn inhibits the protease dipeptidyl peptidase-4 (DPP-4; CD26) that would otherwise cleave and inactivate CXCL12. Ilya...
...ILP100 accelerated wound healing and “met all the safety parameters.” She also told BioCentury that Ilya...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Dermatology

...topical application of the CXCL12-secreting bacteria increased the rate of wound closure. Next steps by Ilya Pharma AB...
...TARGET/MARKER/PATHWAY: Chemokine CXC motif ligand 12 (CXCL12; SDF-1) LICENSING STATUS: Patent application filed; licensed to Ilya Pharma AB...
...online Feb. 5, 2018 doi:10.1073/pnas.1716580115 CONTACT: Mia Phillipson, Uppsala University, Uppsala, Sweden email: mia.phillipson@mcb.uu.se Sandi Wong Lactobacillus reuteri Ilya Pharma AB Uppsala...
BioCentury | Feb 6, 2018
Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

...a study published in Proceedings of the National Academy of Sciences , the co-founders of Ilya Pharma AB...
...chemokine is rapidly broken down by proteases in the extracellular environment. The researchers, headed by Ilya...
...induced by local inflammation or an increase in systemic circulation of L. reuteri or CXCL12. Ilya...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Neurology

...23, 2016 doi:10.1523/JNEUROSCI.1188-16.2016 CONTACT: Ilya Bezprozvanny, University of Texas Southwestern Medical Center, Dallas, Texas email: Ilya.Bezprozvanny@UTSouthwestern.edu Hongjiang...
BioCentury | Nov 8, 2012
Distillery Therapeutics

Indication: Neurology

...2012; doi:10.1016/j.chembiol.2012.07.013 Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: ilya.bezprozvanny@utsouthwestern.edu...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Neurology

...Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: Ilya.Bezprozvanny@UTSouthwestern.edu BC...
BioCentury | Jul 30, 2009
Distillery Therapeutics

Indication: Neurology

...Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: ilya.bezprozvanny@UTSouthwestern.edu BC...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Neurology

...5, 2009; doi:10.1523/JNEUROSCI.4411-08.2009 Contact: Ilya Bezprozvanny, University of Texas Southwestern Medical Center, Dallas, Texas e-mail: ilya.bezprozvanny@utsouthwestern.edu BC...
BioCentury | Feb 12, 2007
Analyst Picks & Changes

Analyst picks & changes

...for chronic lymphocytic leukemia (CLL) and relapsed or refractory multiple myeloma (MM). Theravance (THRX) Rodman Ilya...
Items per page:
1 - 10 of 17
BioCentury | Mar 27, 2021
Regulation

March 26 Quick Takes: ADCs from Astellas-Seagen, Gilead under EMA review; plus Pfizer-Lilly, BrainStorm and Ilya

...social media campaign by patients advocating for access to the therapy. Positive Phase I data for Ilya’s...
BioCentury | Jul 27, 2018
Emerging Company Profile

Wound-up bacteria

...contrast, she expects Ilya’s product will need to be applied about once every three days. Ilya...
...turn inhibits the protease dipeptidyl peptidase-4 (DPP-4; CD26) that would otherwise cleave and inactivate CXCL12. Ilya...
...ILP100 accelerated wound healing and “met all the safety parameters.” She also told BioCentury that Ilya...
BioCentury | Feb 13, 2018
Distillery Therapeutics

Dermatology

...topical application of the CXCL12-secreting bacteria increased the rate of wound closure. Next steps by Ilya Pharma AB...
...TARGET/MARKER/PATHWAY: Chemokine CXC motif ligand 12 (CXCL12; SDF-1) LICENSING STATUS: Patent application filed; licensed to Ilya Pharma AB...
...online Feb. 5, 2018 doi:10.1073/pnas.1716580115 CONTACT: Mia Phillipson, Uppsala University, Uppsala, Sweden email: mia.phillipson@mcb.uu.se Sandi Wong Lactobacillus reuteri Ilya Pharma AB Uppsala...
BioCentury | Feb 6, 2018
Preclinical News

Bacteria that secrete CXCL12 could enhance wound healing

...a study published in Proceedings of the National Academy of Sciences , the co-founders of Ilya Pharma AB...
...chemokine is rapidly broken down by proteases in the extracellular environment. The researchers, headed by Ilya...
...induced by local inflammation or an increase in systemic circulation of L. reuteri or CXCL12. Ilya...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Neurology

...23, 2016 doi:10.1523/JNEUROSCI.1188-16.2016 CONTACT: Ilya Bezprozvanny, University of Texas Southwestern Medical Center, Dallas, Texas email: Ilya.Bezprozvanny@UTSouthwestern.edu Hongjiang...
BioCentury | Nov 8, 2012
Distillery Therapeutics

Indication: Neurology

...2012; doi:10.1016/j.chembiol.2012.07.013 Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: ilya.bezprozvanny@utsouthwestern.edu...
BioCentury | Oct 13, 2011
Distillery Therapeutics

Indication: Neurology

...Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: Ilya.Bezprozvanny@UTSouthwestern.edu BC...
BioCentury | Jul 30, 2009
Distillery Therapeutics

Indication: Neurology

...Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas e-mail: ilya.bezprozvanny@UTSouthwestern.edu BC...
BioCentury | Feb 12, 2009
Distillery Therapeutics

Indication: Neurology

...5, 2009; doi:10.1523/JNEUROSCI.4411-08.2009 Contact: Ilya Bezprozvanny, University of Texas Southwestern Medical Center, Dallas, Texas e-mail: ilya.bezprozvanny@utsouthwestern.edu BC...
BioCentury | Feb 12, 2007
Analyst Picks & Changes

Analyst picks & changes

...for chronic lymphocytic leukemia (CLL) and relapsed or refractory multiple myeloma (MM). Theravance (THRX) Rodman Ilya...
Items per page:
1 - 10 of 17